Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: degarelix Clear all
Completed Not applicable Interventional Results available

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

NCT02489357
View directory record Official record
Conditions
Stage IV Prostate Cancer
Interventions
Cryosurgery, Degarelix, Laboratory Biomarker Analysis, Pembrolizumab
Procedure · Drug · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
View directory record Official record
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

A Study of Degarelix in Patients With Prostate Cancer

NCT00928434
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
59
States / cities
Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

NCT03358563
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

NCT00295750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide 7.5 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 6, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

NCT01377389
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Leuprolide, Goserelin, Degarelix
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 6, 2026, 6:29 PM EDT
Active, not recruiting Phase 2 Interventional

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Biological · Procedure · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

NCT00117949
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
12
States / cities
Anaheim, California • Laguna Woods, California • San Bernardino, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

NCT02472275
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Detroit, Michigan • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 6, 2026, 6:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
326
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

NCT02560051
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 6, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

NCT00117312
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
12
States / cities
Anaheim, California • Laguna Woods, California • San Bernardino, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

NCT05617885
View directory record Official record
Conditions
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
Interventions
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
Drug
Lead sponsor
Praful Ravi, MB BCHir, MRCP
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

NCT02494713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 6, 2026, 6:29 PM EDT
Active, not recruiting Phase 2 Interventional

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

NCT05189457
View directory record Official record
Conditions
Prostate Cancer, Stage IV Prostate Cancer
Interventions
Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel, Tislelizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 6, 2026, 6:29 PM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT02278185
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Enzalutamide, leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, degarelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 6, 2026, 6:29 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02159690
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
Drug
Lead sponsor
Kenneth Pienta, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 6, 2026, 6:29 PM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

NCT07455903
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

NCT01751451
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 6, 2026, 6:29 PM EDT